Search
Sulbutiamine
go.drugbank.com/drugs/DB13416InvestigationalThe chronic administration of the drug has demonstrated to improve long term memory formation in mice. … While its other uses include improvement of erectile dysfunction and reduction of psycho-behavioural inhibition, sulbutiamine showed evidence of modulatory effect on dopaminergic and glutamatergic cortical
Products: SULBRIMO Capsule 200mgNKG2D-ACE2 CAR-NK Cell
go.drugbank.com/drugs/DB15727InvestigationalChimeric antigen receptors (CARs) are artificial receptors consisting of an antibody-derived antigen binding domain and transmembrane and signaling domains from T-cell receptor signalling moieties.
VH3739937
go.drugbank.com/drugs/DB25287InvestigationalVH3739937 is under investigation in clinical trial NCT06533280 (VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect
Freneslerbart
go.drugbank.com/drugs/DB19080InvestigationalFreneslerbart is under investigation in clinical trial NCT04981717 (A Study to Examine the Efficacy and Safety of Anti-fel D 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic
Tanogitran
go.drugbank.com/drugs/DB21367InvestigationalTanogitran is under investigation in clinical trial NCT02254057 (Tolerability and Pharmacokinetics/-Dynamics of Single Rising Doses BIBT 986 BS in Healthy Male Subjects).
Crelosidenib
go.drugbank.com/drugs/DB21642InvestigationalCrelosidenib is under investigation in clinical trial NCT04603001 (Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations).
Rosabulin
go.drugbank.com/drugs/DB20161InvestigationalRosabulin is under investigation in clinical trial NCT00276913 (A Phase I Study of STA-5312 in Subjects With Advanced or Metastatic Solid Tumors).
Macozinone
go.drugbank.com/drugs/DB14821InvestigationalMacozinone is under investigation in clinical trial NCT03036163 (Phase 1 Study of PBTZ169).
JQ1
go.drugbank.com/drugs/DB17021ExperimentalFirst-in-class potent and selective inhibitor of the BRD4 signaling pathway.[A252967]
NKX101
go.drugbank.com/drugs/DB18131InvestigationalNKX101 is an investigational allogeneic chimeric antigen receptor (CAR)-natural killer cell therapy.
Synonyms: a fourth generation activating chimeric receptor (ACR) natural killer (NK) cell therapy engineered with an NKG2D ACR, OX40 costimulatory domain, CD3zeta signaling moiety, and membrane bound IL-15 (mb-IL15